Lifotronic(SH:688389) Ge Long Hui A P P·2026-02-27 15:51Core Viewpoint - Pumen Technology (688389.SH) reported a decline in revenue and net profit for the fiscal year 2025, attributed to domestic healthcare payment reforms and price adjustments in some products [1] Financial Performance - The company achieved total operating revenue of 1.038 billion yuan, a year-on-year decrease of 9.60% [1] - The net profit attributable to the parent company was 186 million yuan, down 46.12% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 166 million yuan, a decrease of 49.28% year-on-year [1] Business Operations - Domestic business revenue declined compared to the same period last year due to industry policy impacts [1] - International marketing business showed stable growth, with ongoing efforts in regional coverage, localized services, and market access [1] - The company remains focused on its core business strategy, emphasizing in vitro diagnostics, clinical medicine, dermatology aesthetics, and consumer health markets [1] - Continuous investment in R&D and marketing is maintained to enrich product offerings and expand market reach [1]